Contact us Demo our platform

Case Study

Metabolomics Identifies Preclinical Biomarker of Acute Renal Injury

The identification of this biomarker would not have been possible without the use of metabolomics analysis.

The findings revealed a practical path forward toward the development of a targeted panel that could be used to screen plasma from mice treated with other related compounds targeting the same indication. This screen allowed researchers to identify a backup compound that did not cause renal toxicity while still achieving target engagement and eliciting a therapeutic effect. These results illustrate that metabolomics is a powerful tool that can deliver actionable insights for toxicity assessment.

Talk With An Expert About Your Project
I

WATCH THE VIDEO

The findings revealed a practical path forward toward the development of a targeted panel that could be used to screen plasma from mice treated with other related compounds targeting the same indication. This screen allowed researchers to identify a backup compound that did not cause renal toxicity while still achieving target engagement and eliciting a therapeutic effect. These results illustrate that metabolomics is a powerful tool that can deliver actionable insights for toxicity assessment.

Talk With An Expert About Your Project

The Challenge: Lack of Translatable Biomarkers

A potent nicotinic acid receptor (NAR) agonist, SCH 900424, was being developed for the treatment of dyslipidemia. Unfortunately, research indicated that it caused rapid onset morbidity and acute renal failure in mice.

To understand the mechanisms behind the toxicity, the Metabolon Global Discovery Panel identified small molecule biomarkers of acute kidney injury (AKI) that could aid in a better understanding of SCH 900424-induced toxicity in mice.1

Plasma and urine samples from mice treated with a range of compound doses were shipped to Metabolon for analysis on the Metabolon Global Discovery Panel which employs a proprietary reference library of 5,400+ compounds to identify endogenous metabolites.

Microbiome-Related Compound Demonstrates Sensitive Response

The results of this metabolomics study identified 3-indoxyl sulfate as a sensitive plasma marker for renal failure. 3-indoxyl sulfate is a microbiome-derived metabolite originating from tryptophan. Bacteria within the gut first convert dietary tryptophan into indole, which is then further metabolized to 3-indoxyl sulfate in the liver and is typically destined for urinary excretion. 3-indoxyl sulfate is a known renal toxin that accumulates in the blood of uremic animals or in patients with chronic renal failure.

Mechanistically, 3-indoxyl sulfate is thought to promote renal failure by damaging tubular cells through modulation of OAT1 and OAT3 transporters, which are expressed on the basal lateral membrane of the proximal and distal tubules. 3-indoxyl sulfate was shown here to be a more sensitive marker of kidney toxicity than other established renal response markers, including creatinine, urea, and p-cresol sulfate.

The Outcome: Using Metabolomics to Deliver Actionable Insights for Assessing Toxicity

Metabolomics data revealed high plasma levels of 3-indoxyl sulfate with acute renal failure; the validity and translatability of this marker was supported by 3-indoxyl sulfate’s known role as a uremic toxin in humans. More importantly, the findings revealed a practical path forward toward the development of a targeted panel that could be used to screen plasma from mice treated with other related compounds targeting the same indication. This screen allowed researchers to identify a backup compound that did not cause renal toxicity while still achieving target engagement and eliciting a therapeutic effect. These results illustrate that metabolomics is a powerful tool that can deliver actionable insights for toxicity assessment.

Metabolon helped researchers to:

  • Obtain actionable insights with respect to the mechanism of compound-induced toxicity including the identification of a metabolite biomarker of renal failure
  • Develop a targeted panel used to screen backup compounds
  • Identify compounds directed against the same target that did not cause renal toxicity

The identification of this biomarker would not have been possible without the use of metabolomics analysis. In addition, Metabolon’s state-of-the-art technology played a crucial role in helping the researchers identify this potential marker of toxicity.

References

1. Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, Alton KB. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol. 2011;255(1):48-56. doi:10.1016/j.taap.2011.05.015

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.